DOCSLIB.ORG

FOXN3 Hyperglycemic Risk Allele and Insulin Sensitivity in Humans

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FOXN3 Hyperglycemic Risk Allele and Insulin Sensitivity in Humans Metabolism Open access Original research BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2019-000688 on 30 August 2019. Downloaded from FOXN3 hyperglycemic risk allele and insulin sensitivity in humans Melissa L Erickson,1 Santhosh Karanth,2 Eric Ravussin,1 Amnon Schlegel 2 To cite: Erickson ML, ABSTRACT Karanth S, Ravussin E, Objective The rs8004664 variation within the FOXN3 Significance of this study et al. FOXN3 hyperglycemic gene is significantly and independently associated with risk allele and insulin fasting blood glucose in humans. We have previously What is already known about this subject? sensitivity in humans. shown that the hyperglycemia risk allele (A) increases ► The fasting hyperglycemia risk allele of the BMJ Open Diab Res Care FOXN3 expression in primary human hepatocytes; over- rs8004664 variation in the FOXN3 gene increases 2019;7:e000688. doi:10.1136/ expression of FOXN3 in the liver and is associated bmjdrc-2019-000688 expression of human FOXN3 in zebrafish liver increases fasting blood glucose; and heterozygous deletion of the with blunted suppression of glucagon during an oral zebrafish orthologfoxn3 decreases fasting blood glucose. glucose tolerance test. Received 15 April 2019 Paralleling these model organism findings, we found ► Over-expression of FOXN3 in liver increases, where- Revised 6 August 2019 that rs8004664 A|A homozygotes had blunted glucagon as knockout of the FOXN3 ortholog decreases fast- Accepted 9 August 2019 suppression during an oral glucose tolerance test. Here, ing blood glucose in zebrafish. we test associations between insulin sensitivity and the What are the new Findings? rs8004664 variation. ► The role of FOXN3 in modulating insulin sensitivity Research design and methods 92 participants was not known. (49±13 years, body mass index: 32±6 kg/m2, 28 with ► We genotyped a cohort of subjects who underwent and 64 without type 2 diabetes mellitus) were genotyped high-dose euglycemic-hyperinsulinemic clamp for at rs8004664. Insulin sensitivity was measured by the the rs8004664. euglycemic-hyperinsulinemic clamp technique. The fasting hyperglycemia variant of rs8004664 copyright. Results The “A” allele frequency was 59%; the protective ► was associated with increased glucose disposal in (G) allele frequency was 41% (A|A: n=29; G|G: n=12; A|G: female subjects, but not in men or the combined n=50). Clamp-measured glucose disposal rate (GDR) was cohort. not different by genotype (F=0.046, p=0.96) or by “A” allele carrier (p=0.36). Female G|G homozygotes had better How might these results change the focus of insulin sensitivity compared to female “A” allele carriers research or clinical practice? (GDR; G|G: 9.9±3.0 vs A|A+A|G: 7.1±3.0 mg/kg fat-free ► FOXN3 may modulate insulin sensitivity in a sexually mass+17.7/min; p=0.04). Insulin sensitivity was not dimorphic manner. different by genotype or by “A” allele carriers. Conclusion The rs8004664 variation within the FOXN3 gene may modulate insulin sensitivity in women. http://drc.bmj.com/ in livers over-expressing FOXN3: the MYC ortholog mycb transcript, which encodes INTRODUCTION a driver of liver glucose utilization during © Author(s) (or their 4 employer(s)) 2019. Re-use In a large cohort of non-diabetic subjects, fasting, was strongly down-regulated. We permitted under CC BY-NC. No the single nucleotide variation rs8004664 showed that FOXN3 directly represses MYC commercial re-use. See rights within the first intron of the FOXN3 gene in expression.2 This indicates that liver FOXN3 and permissions. Published humans was found to be significantly and increases fasting blood glucose by repressing on September 25, 2021 by guest. Protected by BMJ. 1 independently associated with fasting blood a driver of liver glucose utilization, providing Pennington Biomedical 1 2 Research Center, Louisiana glucose. The molecular mechanism for how more glucose for export from the liver. State University System, Baton this variation increases the fasting blood In follow-up investigations, we found that Rouge, Louisiana, USA glucose set-point remains elusive; neverthe- glucagon injection into mice rapidly decreases 2University of Utah Molecular less, we previously showed that the fasting liver FOXN3 protein, indicating hormonal Medicine Program and the hyperglycemia allele at rs804464 increases regulation of FOXN3. When we prepared a Departments of Internal FOXN3 expression in primary human viable loss-of-function mutation in the orthol- Medicine, Biochemistry, and 2 Nutrition and Integrative hepatocytes. We modeled this increased liver ogous foxn3 gene, we observed decreased Physiology, University of Utah FOXN3 expression by over-expressing the fasting blood glucose, blood glucagon, and School of Medicine, Salt Lake human FOXN3 cDNA in zebrafish livers and alpha cell mass.5 Concordantly, over-expres- City, Utah, USA observed an increase in fasting blood glucose sion of human FOXN3 in zebrafish liver Correspondence to without any additional dietary challenge. increased alpha cell mass in the zebrafish 3 Dr Amnon Schlegel; Since FOXN3 is a transcriptional repressor, endocrine pancreas. In this second study, amnons@ u2m2. utah. edu we performed whole transcriptome analyses we also explored the effect of the rs8004664 BMJ Open Diab Res Care 2019;7:e000688. doi:10.1136/bmjdrc-2019-000688 1 Metabolism BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2019-000688 on 30 August 2019. Downloaded from variation on oral glucose tolerance in a large cohort of Table 1 Participant characteristics and glucose disposal human subjects: rs8004644 hyperglycemia risk allele rate by rs8004664 genotype carriers show diminished suppression of glucagon over Genotype Genotype the oral glucose tolerance test (as reflected by decreased A|A+A|G G|G area below baseline), but show no differences in fasting Characteristic (n=79) (n=13) P value glucagon.5 Age (y) 50±13 46±15 0.32 Our working model for how FOXN3 regulates fasting glucose does not exclude a potential role for insulin sensi- Sex (M/F) 36/43 7/6 NA 2 tivity, and therefore glucose disposal rate (GDR) during BMI (kg/m ) 33±6 32±7 0.91 a glucose clamp. Here, we tested in a cohort of adults Body weight (kg) 93±19 93±22 0.99 with and without type 2 diabetes whether the rs8004664 FFM (kg) 58.9±11.7 59.6±14.0 0.85 variation modulates insulin-mediated glucose uptake by Fasting glucose (mg/dL) 102±17 102±12 0.97 examining associations between rs8004664 variants and Fasting insulin (μU/mL) 15±7 17±21 0.56 insulin sensitivity measured by the gold-standard euglyce- mic-hyperinsulinemic clamp technique.6 HOMA-IR 3.9±2.1 4.6±6.2 0.40 DXA (% Fat) 36±9 35±8 0.83 Cholesterol (mg/dL) 203±42 200±44 0.79 METHODS HDL (mg/dL) 50±12 53±17 0.49 Study population LDL (mg/dL) 120±36 117±43 0.80 In this single group cross-sectional design, 92 partici- Triglycerides (mg/dL) 165±115 148±118 0.61 pants who previously underwent a euglycemic-hyperinsu- Diabetes status (Y/N) 25/54 3/10 NA 6 linemic clamp were genotyped at the rs8004664 variant. Glucose disposal (mg/kg 6.7±2.9 7.5±3.1 0.36 Participants were initially part of a larger prospective FFM +17.7/min) study called “The Pennington Center Longitudinal Study” designed to assess the effects of obesity and BMI, body mass index; FFM, fat-free mass; HDL, high-density lipoprotein; LDL, low-density lipoprotein. lifestyle factors on the chronic disease development, including type 2 diabetes mellitus. The current study copyright. utilized a subset of participants (with available DNA) Genotyping from the original cohort, consisting of 92 white adults. DNA was extracted from buffy coat of blood samples Participants were categorized as having type 2 diabetes (Qiagen Puregene Blood Core Kit #158389). Geno- by self-report (“yes” response to having diabetes) or by typing of the rs8004664 variant was completed using fasting plasma glucose 126 mg/dL, on study visit. ≥ a TaqMan SNP Genotyping Assay (ThermoFisher ID C__29386020_10) as previously described.5 Anthropometrics/body composition As previously described,6 metabolic body weight and Statistical analysis height were measured, and body mass index was calcu- Data are presented as mean±SD, unless otherwise noted. lated from these respective values. Per cent body fat SPSS (IBM V. 25) was used for statistical analysis. Partic- http://drc.bmj.com/ was determined from dual-energy X-ray absorptiometry ipants were grouped by genotype (G|G, A|G, and A|A), (DXA, Hologics QDR 4500A; Hologics, Bedford, MA, and differences in metabolic outcomes were tested using USA). Fat mass and fat-free mass (FFM) were calculated one-way analysis of variance. Secondarily, participants from DXA-measured whole body per cent fat and meta- were grouped by hyperglycemic risk-carrying allele versus bolic body weight. protective allele homozygotes (A|G+A|G combined vs G|G), and differences were tested using unpaired on September 25, 2021 by guest. Protected Student’s t-test. Significance was accepted at p=0.05. To Insulin sensitivity explore the role of type 2 diabetes status on the relation- Peripheral insulin sensitivity was measured using the ship between genetic variants and metabolic outcomes, gold-standard euglycemic-hyperinsulinemic clamp participants were categorized by diabetes status and a technique, as previously described.6 Briefly, plasma similar analysis was performed among these two groups glucose was clamped between 90 and 100 mg/dL during (those with and without type 2 diabetes). Furthermore, continuous insulin infusion (120 mU/m2/min). GDRs the relationship between genetic variants and metabolic presented herein are normalized for metabolic size of outcomes was also performed separately among women the participant (FFM +17.7) as well as average insulin and men. concentrations during steady state of the clamp proce- dure.7 Average insulin concentrations measured during steady state of the clamp for the entire study cohort was RESULTS 227.1±68 µU/mL.
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Supplemental Materials ZNF281 Enhances Cardiac Reprogramming
    Supplemental Materials ZNF281 enhances cardiac reprogramming by modulating cardiac and inflammatory gene expression Huanyu Zhou, Maria Gabriela Morales, Hisayuki Hashimoto, Matthew E. Dickson, Kunhua Song, Wenduo Ye, Min S. Kim, Hanspeter Niederstrasser, Zhaoning Wang, Beibei Chen, Bruce A. Posner, Rhonda Bassel-Duby and Eric N. Olson Supplemental Table 1; related to Figure 1. Supplemental Table 2; related to Figure 1. Supplemental Table 3; related to the “quantitative mRNA measurement” in Materials and Methods section. Supplemental Table 4; related to the “ChIP-seq, gene ontology and pathway analysis” and “RNA-seq” and gene ontology analysis” in Materials and Methods section. Supplemental Figure S1; related to Figure 1. Supplemental Figure S2; related to Figure 2. Supplemental Figure S3; related to Figure 3. Supplemental Figure S4; related to Figure 4. Supplemental Figure S5; related to Figure 6. Supplemental Table S1. Genes included in human retroviral ORF cDNA library. Gene Gene Gene Gene Gene Gene Gene Gene Symbol Symbol Symbol Symbol Symbol Symbol Symbol Symbol AATF BMP8A CEBPE CTNNB1 ESR2 GDF3 HOXA5 IL17D ADIPOQ BRPF1 CEBPG CUX1 ESRRA GDF6 HOXA6 IL17F ADNP BRPF3 CERS1 CX3CL1 ETS1 GIN1 HOXA7 IL18 AEBP1 BUD31 CERS2 CXCL10 ETS2 GLIS3 HOXB1 IL19 AFF4 C17ORF77 CERS4 CXCL11 ETV3 GMEB1 HOXB13 IL1A AHR C1QTNF4 CFL2 CXCL12 ETV7 GPBP1 HOXB5 IL1B AIMP1 C21ORF66 CHIA CXCL13 FAM3B GPER HOXB6 IL1F3 ALS2CR8 CBFA2T2 CIR1 CXCL14 FAM3D GPI HOXB7 IL1F5 ALX1 CBFA2T3 CITED1 CXCL16 FASLG GREM1 HOXB9 IL1F6 ARGFX CBFB CITED2 CXCL3 FBLN1 GREM2 HOXC4 IL1F7
    [Show full text]
  • FOXN3 Inhibits Cell Proliferation Though Regulating E2F1 in Prostate Cancer
    Research Paper FOXN3 Inhibits Cell Proliferation though Regulating E2F1 in Prostate Cancer NING. ZHANG, HAIJUN. YANG* AND QINGQI. ZENG Department of Traditional Chinese Medicine, Jiangsu Health Vocational College, No. 69 Huangshanling Road, Nanjing, Jiangsu 211800, China Zhang et al.: FOXN3 Inhibits Cell Proliferation in Prostate Cancer In this study, it was demonstrated that forkhead box N3 was downregulated in prostate cancer tissues compared to the matched normal adjacent tissues. Prostate cancer patients with high forkhead box N3 expression more frequently had longer survival (P<0.05) than those with low forkhead box N3 expression. Forkhead box N3 inhibited prostate cancer cell proliferation in vitro and in vivo. In addition, forkhead box N3 repressed expression of E2F1, a reported potential oncogene at the messenger ribonucleic acid and protein levels. Taken together, these data delineate an unrecognized function of forkhead box N3 as a tumor suppressor in prostate cancer via repressing the expression of E2F1. Key words: Prostate cancer, FOXN3, E2F1, cell proliferation As a common urogenital system malignant tumor in could down-regulate E2F5 in human cells to control men, prostate cancer (PC) threatens men’s health and cell cycle or inhibit protein biosynthesis[6]. In addition, becomes an important cause of death in the elderly[1]. studies have shown that FOXN3 is significantly The incidence of PC has increased in most countries downregulated in several cancer tissues including oral and PC represents a major disease burden worldwide in laryngeal carcinoma hepatocellular carcinoma, the past decade[2,3]. Treatment options for PC depended squamous cell carcinoma and colon cancer[6,9,10].
    [Show full text]
  • Appendix 2. Significantly Differentially Regulated Genes in Term Compared with Second Trimester Amniotic Fluid Supernatant
    Appendix 2. Significantly Differentially Regulated Genes in Term Compared With Second Trimester Amniotic Fluid Supernatant Fold Change in term vs second trimester Amniotic Affymetrix Duplicate Fluid Probe ID probes Symbol Entrez Gene Name 1019.9 217059_at D MUC7 mucin 7, secreted 424.5 211735_x_at D SFTPC surfactant protein C 416.2 206835_at STATH statherin 363.4 214387_x_at D SFTPC surfactant protein C 295.5 205982_x_at D SFTPC surfactant protein C 288.7 1553454_at RPTN repetin solute carrier family 34 (sodium 251.3 204124_at SLC34A2 phosphate), member 2 238.9 206786_at HTN3 histatin 3 161.5 220191_at GKN1 gastrokine 1 152.7 223678_s_at D SFTPA2 surfactant protein A2 130.9 207430_s_at D MSMB microseminoprotein, beta- 99.0 214199_at SFTPD surfactant protein D major histocompatibility complex, class II, 96.5 210982_s_at D HLA-DRA DR alpha 96.5 221133_s_at D CLDN18 claudin 18 94.4 238222_at GKN2 gastrokine 2 93.7 1557961_s_at D LOC100127983 uncharacterized LOC100127983 93.1 229584_at LRRK2 leucine-rich repeat kinase 2 HOXD cluster antisense RNA 1 (non- 88.6 242042_s_at D HOXD-AS1 protein coding) 86.0 205569_at LAMP3 lysosomal-associated membrane protein 3 85.4 232698_at BPIFB2 BPI fold containing family B, member 2 84.4 205979_at SCGB2A1 secretoglobin, family 2A, member 1 84.3 230469_at RTKN2 rhotekin 2 82.2 204130_at HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 81.9 222242_s_at KLK5 kallikrein-related peptidase 5 77.0 237281_at AKAP14 A kinase (PRKA) anchor protein 14 76.7 1553602_at MUCL1 mucin-like 1 76.3 216359_at D MUC7 mucin 7,
    [Show full text]
  • Supplementary Material Computational Prediction of SARS
    Supplementary_Material Computational prediction of SARS-CoV-2 encoded miRNAs and their putative host targets Sheet_1 List of potential stem-loop structures in SARS-CoV-2 genome as predicted by VMir. Rank Name Start Apex Size Score Window Count (Absolute) Direct Orientation 1 MD13 2801 2864 125 243.8 61 2 MD62 11234 11286 101 211.4 49 4 MD136 27666 27721 104 205.6 119 5 MD108 21131 21184 110 204.7 210 9 MD132 26743 26801 119 188.9 252 19 MD56 9797 9858 128 179.1 59 26 MD139 28196 28233 72 170.4 133 28 MD16 2934 2974 76 169.9 71 43 MD103 20002 20042 80 159.3 403 46 MD6 1489 1531 86 156.7 171 51 MD17 2981 3047 131 152.8 38 87 MD4 651 692 75 140.3 46 95 MD7 1810 1872 121 137.4 58 116 MD140 28217 28252 72 133.8 62 122 MD55 9712 9758 96 132.5 49 135 MD70 13171 13219 93 130.2 131 164 MD95 18782 18820 79 124.7 184 173 MD121 24086 24135 99 123.1 45 176 MD96 19046 19086 75 123.1 179 196 MD19 3197 3236 76 120.4 49 200 MD86 17048 17083 73 119.8 428 223 MD75 14534 14600 137 117 51 228 MD50 8824 8870 94 115.8 79 234 MD129 25598 25642 89 115.6 354 Reverse Orientation 6 MR61 19088 19132 88 197.8 271 10 MR72 23563 23636 148 188.8 286 11 MR11 3775 3844 136 185.1 116 12 MR94 29532 29582 94 184.6 271 15 MR43 14973 15028 109 183.9 226 27 MR14 4160 4206 89 170 241 34 MR35 11734 11792 111 164.2 37 52 MR5 1603 1652 89 152.7 118 53 MR57 18089 18132 101 152.7 139 94 MR8 2804 2864 122 137.4 38 107 MR58 18474 18508 72 134.9 237 117 MR16 4506 4540 72 133.8 311 120 MR34 10010 10048 82 132.7 245 133 MR7 2534 2578 90 130.4 75 146 MR79 24766 24808 75 127.9 59 150 MR65 21528 21576 99 127.4 83 180 MR60 19016 19049 70 122.5 72 187 MR51 16450 16482 75 121 363 190 MR80 25687 25734 96 120.6 75 198 MR64 21507 21544 70 120.3 35 206 MR41 14500 14542 84 119.2 94 218 MR84 26840 26894 108 117.6 94 Sheet_2 List of stable stem-loop structures based on MFE.
    [Show full text]
  • Thesis Template
    Characterisation of the Co-chaperone Small Glutamine-rich Tetratricopeptide Repeat containing protein alpha as a Regulator of Androgen Receptor Activity in Prostate Cancer Cells A thesis submitted to the University of Adelaide in total fulfilment of the requirements for the degree of Doctor of Philosophy by ANDREW PAUL TROTTA B.Sc. (Mol. Biol.), B.Sc. (Hons) Department of Medicine The University of Adelaide Adelaide, South Australia July 2011 This thesis is dedicated to my mum and dad. Thank you for all your love and support. DECLARATION I ACKNOWLEDGEMENTS II ABBREVIATIONS V ABSTRACT X CHAPTER 1: INTRODUCTION 2 1.1 Overview 2 1.2 Development of the prostate 4 1.2.1 Androgen physiology 4 1.2.2 Development of the normal prostate 5 1.3 Prostate cancer and progression 9 1.3.1 Pathogenesis 9 1.4 Diagnosis 10 1.4.1 Clinically localized and advanced disease 11 1.5 Treatment 12 1.5.1 Localised Disease 12 1.5.2 Metastatic Disease 12 1.6 The androgen signalling axis 14 1.6.1 The androgen receptor 15 1.6.2 The androgen receptor gene 16 1.6.3 The androgen receptor protein and domains 19 1.7 Androgen receptor co-regulators 24 1.7.1 Co-activators 24 1.7.2 Co-repressors 25 1.7.3 Chaperones 26 1.8 The molecular chaperone complex and androgen receptor maturation 27 1.8.1 Chaperones involved in ligand binding and nuclear translocation 32 1.8.2 Chaperones and transcriptional activation 37 1.9 Chaperones in prostate cancer 37 1.10 Chaperones as therapeutic targets 39 1.11 Tetratricopeptide repeat containing co-chaperones 40 1.11.1 Structure of TPR domain
    [Show full text]
  • Activin-A Limits Th17 Pathogenicity and Autoimmune Neuroinflammation Via CD39 and CD73 Ectonucleotidases and Hif1-Α–Dependent Pathways
    Correction IMMUNOLOGY AND INFLAMMATION Correction for “Activin-A limits Th17 pathogenicity and autoim- mune neuroinflammation via CD39 and CD73 ectonucleotidases and Hif1-α–dependent pathways,” by Ioannis Morianos, Aikaterini I. Trochoutsou, Gina Papadopoulou, Maria Semitekolou, Aggelos Banos, Dimitris Konstantopoulos, Antigoni Manousopoulou, Maria Kapasa, Ping Wei, Brett Lomenick, Elise Belaidi, Themis Kalamatas, Klinta Karageorgiou, Triantafyllos Doskas, Federica Sallusto, Fan Pan, Spiros D. Garbis, Francisco J. Quintana, and Georgina Xanthou, which was first published May 14, 2020; 10.1073/ pnas.1918196117 (Proc. Natl. Acad. Sci. U.S.A. 117, 12269–12280). The authors note that an additional affiliation should be listed for Federica Sallusto. The new affiliation should appear as Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland. The corrected author and affiliation lines appearbelow.Theonlineversion has been corrected. Ioannis Morianosa,AikateriniI.Trochoutsoua,Gina CORRECTION Papadopouloua, Maria Semitekoloua, Aggelos Banosb, Dimitris Konstantopoulosc, Antigoni Manousopouloud, Maria Kapasae, Ping Weif, Brett Lomenickg, Elise Belaidih,i, Themis Kalamatasj, Klinta Karageorgiouk, Triantafyllos Doskasl, Federica Sallustom,n, Fan Panf, Spiros D. Garbisg, Francisco J. Quintanao,p, and Georgina Xanthoua aCellular Immunology Laboratory, Biomedical Research Foundation of the Academy of Athens, 115 27 Athens, Greece; bDivision of Immunobiology, Biomedical Research Foundation of the Academy
    [Show full text]
  • Transforming Growth Factor ß1-Mediated Functional Inhibition Of
    Myelodysplastic Syndromes SUPPLEMENTARY APPENDIX Transforming growth factor 1- mediated functional inhibition of mesenchymal stromal celβls in myelodysplastic syndromes and acute myeloid leukemia Stefanie Geyh, 1* Manuel Rodríguez-Paredes, 1,2 * Paul Jäger, 1 Annemarie Koch, 1 Felix Bormann, 2 Julian Gutekunst, 2 Christoph Zilkens, 3 Ulrich Germing, 1 Guido Kobbe, 1 Frank Lyko, 2 Rainer Haas 1 and Thomas Schroeder 1 1Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty; 2Division of Epigenetics, DKFZ- ZMBH Alliance, German Cancer Research Center, Heidelberg and 3Department of Orthopedic Surgery, University of Duesseldorf, Medical Faculty, Germany *SG and MR-P contributed equally to this work. ©2018 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2017.186734 Received: December 19, 2017. Accepted: May 14, 2018. Pre-published: May 17, 2018. Correspondence: [email protected] Figure S1 Downregulated genes Downregulated genes Upregulated Figure S1. Heatmaps showing the 50 most upregulated and downregulated genes between the 3 healthy MSC controls and the 9 RCMD-, RAEB- and AML-derived MSC samples. Color scale depicts the rlog-transformed FPKM values for each gene and every sample. Figure S2 Downregulated genes Downregulated genes Upregulated Figure S2. Heatmaps showing the 50 most upregulated and downregulated genes between the 3 healthy MSC controls and the 3 RCMD, RAEB and AML MSC samples, respectively. Color scales depict the rlog-transformed FPKM values for each gene and every sample. Figure S3 A. B. 0.0015 *** ** <-3 -2 0.0010 RCMD RAEB AML -1 0 1 0.0005 Log2FC LTF 2 CCL26/GAPDH INHBB >3 0.0000 TGFB2 y S h D ML M A ealt ll LTF H a EGF 0.003 *** ** INHBB TGFB2 0.002 INHBB IGFBP7 0.001 GDF11 LIF/GAPDH BMP1 0.000 y L th M TNFSF12 l A FGF13 ea ll MDS H a FGF13 0.0015 * TNFSF10 TNFSF10 0.0010 0.0005 SPP1/GAPDH 0.0000 y th l AML ea H all MDS Figure S3.
    [Show full text]
  • CREB-Dependent Transcription in Astrocytes: Signalling Pathways, Gene Profiles and Neuroprotective Role in Brain Injury
    CREB-dependent transcription in astrocytes: signalling pathways, gene profiles and neuroprotective role in brain injury. Tesis doctoral Luis Pardo Fernández Bellaterra, Septiembre 2015 Instituto de Neurociencias Departamento de Bioquímica i Biologia Molecular Unidad de Bioquímica y Biologia Molecular Facultad de Medicina CREB-dependent transcription in astrocytes: signalling pathways, gene profiles and neuroprotective role in brain injury. Memoria del trabajo experimental para optar al grado de doctor, correspondiente al Programa de Doctorado en Neurociencias del Instituto de Neurociencias de la Universidad Autónoma de Barcelona, llevado a cabo por Luis Pardo Fernández bajo la dirección de la Dra. Elena Galea Rodríguez de Velasco y la Dra. Roser Masgrau Juanola, en el Instituto de Neurociencias de la Universidad Autónoma de Barcelona. Doctorando Directoras de tesis Luis Pardo Fernández Dra. Elena Galea Dra. Roser Masgrau In memoriam María Dolores Álvarez Durán Abuela, eres la culpable de que haya decidido recorrer el camino de la ciencia. Que estas líneas ayuden a conservar tu recuerdo. A mis padres y hermanos, A Meri INDEX I Summary 1 II Introduction 3 1 Astrocytes: physiology and pathology 5 1.1 Anatomical organization 6 1.2 Origins and heterogeneity 6 1.3 Astrocyte functions 8 1.3.1 Developmental functions 8 1.3.2 Neurovascular functions 9 1.3.3 Metabolic support 11 1.3.4 Homeostatic functions 13 1.3.5 Antioxidant functions 15 1.3.6 Signalling functions 15 1.4 Astrocytes in brain pathology 20 1.5 Reactive astrogliosis 22 2 The transcription
    [Show full text]
  • Positional Specificity of Different Transcription Factor Classes Within Enhancers
    Positional specificity of different transcription factor classes within enhancers Sharon R. Grossmana,b,c, Jesse Engreitza, John P. Raya, Tung H. Nguyena, Nir Hacohena,d, and Eric S. Landera,b,e,1 aBroad Institute of MIT and Harvard, Cambridge, MA 02142; bDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139; cProgram in Health Sciences and Technology, Harvard Medical School, Boston, MA 02215; dCancer Research, Massachusetts General Hospital, Boston, MA 02114; and eDepartment of Systems Biology, Harvard Medical School, Boston, MA 02215 Contributed by Eric S. Lander, June 19, 2018 (sent for review March 26, 2018; reviewed by Gioacchino Natoli and Alexander Stark) Gene expression is controlled by sequence-specific transcription type-restricted enhancers (active in <50% of the cell types) and factors (TFs), which bind to regulatory sequences in DNA. TF ubiquitous enhancers (active in >90% of the cell types) (SI Ap- binding occurs in nucleosome-depleted regions of DNA (NDRs), pendix, Fig. S1C). which generally encompass regions with lengths similar to those We next sought to infer functional TF-binding sites within the protected by nucleosomes. However, less is known about where active regulatory elements. In a recent study (5), we found that within these regions specific TFs tend to be found. Here, we char- TF binding is strongly correlated with the quantitative DNA acterize the positional bias of inferred binding sites for 103 TFs accessibility of a region. Furthermore, the TF motifs associated within ∼500,000 NDRs across 47 cell types. We find that distinct with enhancer activity in reporter assays in a cell type corre- classes of TFs display different binding preferences: Some tend to sponded closely to those that are most enriched in the genomic have binding sites toward the edges, some toward the center, and sequences of active regulatory elements in that cell type (5).
    [Show full text]
  • GENOMIC REGULATION of CLOCK FUNCTION a Dissertation Submitted
    GENOMIC REGULATION OF CLOCK FUNCTION A dissertation submitted to Kent State University in partial fulfillment of the requirements for the degree of Doctor of Philosophy by Jessica L. Vespoli July, 2015 © Copyright All rights reserved Dissertation written by Jessica L. Vespoli B.S., University of Pittsburgh Johnstown, 2009 Approved by __________________________________________________ Dr. Eric M. Mintz, Ph.D., Department of Biological Sciences, Doctoral Advisor __________________________________________________ Dr. Gail Fraizer, Ph.D., Department of Biological Sciences __________________________________________________ Dr. Olena Piontkivska, Ph.D., Department of Biological Sciences __________________________________________________ Dr. Aaron Jasnow, Ph.D., Department of Psychological Sciences __________________________________________________ Dr. Fayez Safadi, Ph.D., Department of Anatomy & Neurobiology, NEOMED Accepted by __________________________________________________ Dr. Laura Leff, Ph.D., Chair, Department of Biological Sciences __________________________________________________ Dr. James L. Blank, Ph.D., Dean, College of Arts and Sciences ii Table of Contents Page List of Figures……………………………………………………………………………vii List of Tables……………………………………………………………………………..ix List of Abbreviations……………………………………………………………………...x Acknowledgements……………………………………………………………………...xiv CHAPTER I. Introduction………………………………………………………………. 1 Background on Circadian Rhythms ................................................................................ 1 The Molecular
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0269772 A1 Califano Et Al
    US 20090269772A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0269772 A1 Califano et al. (43) Pub. Date: Oct. 29, 2009 (54) SYSTEMS AND METHODS FOR Publication Classification IDENTIFYING COMBINATIONS OF (51) Int. Cl. COMPOUNDS OF THERAPEUTIC INTEREST CI2O I/68 (2006.01) CI2O 1/02 (2006.01) (76) Inventors: Andrea Califano, New York, NY G06N 5/02 (2006.01) (US); Riccardo Dalla-Favera, New (52) U.S. Cl. ........... 435/6: 435/29: 706/54; 707/E17.014 York, NY (US); Owen A. (57) ABSTRACT O'Connor, New York, NY (US) Systems, methods, and apparatus for searching for a combi nation of compounds of therapeutic interest are provided. Correspondence Address: Cell-based assays are performed, each cell-based assay JONES DAY exposing a different sample of cells to a different compound 222 EAST 41ST ST in a plurality of compounds. From the cell-based assays, a NEW YORK, NY 10017 (US) Subset of the tested compounds is selected. For each respec tive compound in the Subset, a molecular abundance profile from cells exposed to the respective compound is measured. (21) Appl. No.: 12/432,579 Targets of transcription factors and post-translational modu lators of transcription factor activity are inferred from the (22) Filed: Apr. 29, 2009 molecular abundance profile data using information theoretic measures. This data is used to construct an interaction net Related U.S. Application Data work. Variances in edges in the interaction network are used to determine the drug activity profile of compounds in the (60) Provisional application No. 61/048.875, filed on Apr.
    [Show full text]